Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1987

AUTHORS

H. Mabuchi , N. Kamon , H. Fujita , I. Michishita , M. Takeda , K. Kajinami , H. Itoh , T. Wakasugi , R. Takeda

ABSTRACT

Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomas, and premature coronary artery disease (CAD) (1). The disorder results from a complete or partial defect of the LDL receptor (1) that normally controls the degradation of LDL. Reduction of LDL-cholesterol levels has proved to be effective in decreasing the incidence of CAD (2, 3). Compactin (4) and mevinolin (5), competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are effective in lowering cholesterol levels of patients with familial hypercholesterolemia. These drugs lower plasma LDL by decreasing the rate of LDL production and stimulating the production of LDL receptor in the liver (6) (Fig. 1). LDL receptor has a specific binding activity for apolipoproteins B and E (7). The apolipoprotein B is present in very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and LDL (8), which are highly associated with CAD (9, 10). Apolipoproteins A-I and A-II are primary apolipo-proteins in high-density lipoprotein (HDL) (8), and apolipoprotein A-I in patients with CAD has been demonstrated to be decreased (11). More... »

PAGES

260-268

Book

TITLE

Drugs Affecting Lipid Metabolism

ISBN

978-3-642-71704-8
978-3-642-71702-4

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-71702-4_49

DOI

http://dx.doi.org/10.1007/978-3-642-71702-4_49

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051880374


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biochemistry and Metabolomics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Mabuchi", 
        "givenName": "H.", 
        "id": "sg:person.01154062341.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154062341.76"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Kamon", 
        "givenName": "N.", 
        "id": "sg:person.01013672342.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013672342.45"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Fujita", 
        "givenName": "H.", 
        "id": "sg:person.0711142437.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711142437.68"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Michishita", 
        "givenName": "I.", 
        "id": "sg:person.0732262025.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Takeda", 
        "givenName": "M.", 
        "id": "sg:person.0670213705.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670213705.97"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Kajinami", 
        "givenName": "K.", 
        "id": "sg:person.01017622015.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017622015.68"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Itoh", 
        "givenName": "H.", 
        "id": "sg:person.016647555142.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016647555142.20"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Wakasugi", 
        "givenName": "T.", 
        "id": "sg:person.0623417033.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623417033.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Second Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "The Second Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeda", 
        "givenName": "R.", 
        "id": "sg:person.01340001663.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340001663.38"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1987", 
    "datePublishedReg": "1987-01-01", 
    "description": "Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomas, and premature coronary artery disease (CAD) (1). The disorder results from a complete or partial defect of the LDL receptor (1) that normally controls the degradation of LDL. Reduction of LDL-cholesterol levels has proved to be effective in decreasing the incidence of CAD (2, 3). Compactin (4) and mevinolin (5), competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are effective in lowering cholesterol levels of patients with familial hypercholesterolemia. These drugs lower plasma LDL by decreasing the rate of LDL production and stimulating the production of LDL receptor in the liver (6) (Fig. 1). LDL receptor has a specific binding activity\n\nfor apolipoproteins B and E (7). The apolipoprotein B is present in very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and LDL (8), which are highly associated with CAD (9, 10). Apolipoproteins A-I and A-II are primary apolipo-proteins in high-density lipoprotein (HDL) (8), and apolipoprotein A-I in patients with CAD has been demonstrated to be decreased (11).", 
    "editor": [
      {
        "familyName": "Paoletti", 
        "givenName": "Rodolfo", 
        "type": "Person"
      }, 
      {
        "familyName": "Kritchevsky", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "familyName": "Holmes", 
        "givenName": "William L.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-71702-4_49", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-71704-8", 
        "978-3-642-71702-4"
      ], 
      "name": "Drugs Affecting Lipid Metabolism", 
      "type": "Book"
    }, 
    "keywords": [
      "coronary artery disease", 
      "intermediate density lipoprotein", 
      "high-density lipoprotein", 
      "familial hypercholesterolemia", 
      "LDL receptor", 
      "apolipoprotein B", 
      "incidence of CAD", 
      "low-density lipoprotein cholesterol", 
      "LDL cholesterol levels", 
      "serum lipoprotein lipids", 
      "lower plasma LDL", 
      "low-density lipoprotein", 
      "degradation of LDL", 
      "autosomal dominant disorder", 
      "lipoprotein cholesterol", 
      "artery disease", 
      "tendon xanthomas", 
      "apolipoprotein levels", 
      "cholesterol levels", 
      "lipoprotein lipids", 
      "plasma LDL", 
      "LDL production", 
      "density lipoprotein", 
      "CS-514", 
      "hypercholesterolemia", 
      "patients", 
      "LDL", 
      "apolipoprotein A", 
      "coenzyme A (HMG-CoA) reductase", 
      "elevated levels", 
      "dominant disorder", 
      "lipoproteins", 
      "receptors", 
      "term effects", 
      "partial defect", 
      "disorders", 
      "xanthomas", 
      "levels", 
      "competitive inhibitor", 
      "incidence", 
      "disease", 
      "liver", 
      "cholesterol", 
      "inhibitors", 
      "lipids", 
      "mevinolin", 
      "activity", 
      "defects", 
      "rate", 
      "reduction", 
      "effect", 
      "production", 
      "compactin", 
      "reductase", 
      "degradation"
    ], 
    "name": "Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia", 
    "pagination": "260-268", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051880374"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-71702-4_49"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-71702-4_49", 
      "https://app.dimensions.ai/details/publication/pub.1051880374"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-06-01T22:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/chapter/chapter_93.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-71702-4_49"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-71702-4_49'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-71702-4_49'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-71702-4_49'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-71702-4_49'


 

This table displays all metadata directly associated to this object as RDF triples.

173 TRIPLES      23 PREDICATES      81 URIs      74 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-71702-4_49 schema:about anzsrc-for:11
2 anzsrc-for:1101
3 schema:author N452d20ed03b6499398dd997df234eb37
4 schema:datePublished 1987
5 schema:datePublishedReg 1987-01-01
6 schema:description Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomas, and premature coronary artery disease (CAD) (1). The disorder results from a complete or partial defect of the LDL receptor (1) that normally controls the degradation of LDL. Reduction of LDL-cholesterol levels has proved to be effective in decreasing the incidence of CAD (2, 3). Compactin (4) and mevinolin (5), competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are effective in lowering cholesterol levels of patients with familial hypercholesterolemia. These drugs lower plasma LDL by decreasing the rate of LDL production and stimulating the production of LDL receptor in the liver (6) (Fig. 1). LDL receptor has a specific binding activity for apolipoproteins B and E (7). The apolipoprotein B is present in very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and LDL (8), which are highly associated with CAD (9, 10). Apolipoproteins A-I and A-II are primary apolipo-proteins in high-density lipoprotein (HDL) (8), and apolipoprotein A-I in patients with CAD has been demonstrated to be decreased (11).
7 schema:editor Nc9bf2c75f9f84c6e9656834cbf694f42
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N2e4e08a34e2c4e3cbec1bda39c6ef666
12 schema:keywords CS-514
13 LDL
14 LDL cholesterol levels
15 LDL production
16 LDL receptor
17 activity
18 apolipoprotein A
19 apolipoprotein B
20 apolipoprotein levels
21 artery disease
22 autosomal dominant disorder
23 cholesterol
24 cholesterol levels
25 coenzyme A (HMG-CoA) reductase
26 compactin
27 competitive inhibitor
28 coronary artery disease
29 defects
30 degradation
31 degradation of LDL
32 density lipoprotein
33 disease
34 disorders
35 dominant disorder
36 effect
37 elevated levels
38 familial hypercholesterolemia
39 high-density lipoprotein
40 hypercholesterolemia
41 incidence
42 incidence of CAD
43 inhibitors
44 intermediate density lipoprotein
45 levels
46 lipids
47 lipoprotein cholesterol
48 lipoprotein lipids
49 lipoproteins
50 liver
51 low-density lipoprotein
52 low-density lipoprotein cholesterol
53 lower plasma LDL
54 mevinolin
55 partial defect
56 patients
57 plasma LDL
58 production
59 rate
60 receptors
61 reductase
62 reduction
63 serum lipoprotein lipids
64 tendon xanthomas
65 term effects
66 xanthomas
67 schema:name Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia
68 schema:pagination 260-268
69 schema:productId N8a442aba502542d2b6ff0e23615a9d16
70 Nbb7e5d59377943928db0d5cbdcaa30dc
71 schema:publisher Na8772a6295a649758655aa53ff45a11d
72 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051880374
73 https://doi.org/10.1007/978-3-642-71702-4_49
74 schema:sdDatePublished 2022-06-01T22:37
75 schema:sdLicense https://scigraph.springernature.com/explorer/license/
76 schema:sdPublisher Nd34ddf0157a04bc7ad1c969cba5730b3
77 schema:url https://doi.org/10.1007/978-3-642-71702-4_49
78 sgo:license sg:explorer/license/
79 sgo:sdDataset chapters
80 rdf:type schema:Chapter
81 N05dda3e4f741473a9f9b64ca71747723 rdf:first sg:person.0670213705.97
82 rdf:rest Ne1c87b5d9ef64e7b9bdc86e7d50c38ac
83 N2e4e08a34e2c4e3cbec1bda39c6ef666 schema:isbn 978-3-642-71702-4
84 978-3-642-71704-8
85 schema:name Drugs Affecting Lipid Metabolism
86 rdf:type schema:Book
87 N429b8f47125f46f295f81abe385c9d4c rdf:first sg:person.01340001663.38
88 rdf:rest rdf:nil
89 N452d20ed03b6499398dd997df234eb37 rdf:first sg:person.01154062341.76
90 rdf:rest N76a56b00fc9d4a38ab25b360a5d38173
91 N535f4655832b4c8aad9ddee1ddebcb20 schema:familyName Kritchevsky
92 schema:givenName David
93 rdf:type schema:Person
94 N67c9666f2e8e4770a84afdc21f925937 rdf:first sg:person.0732262025.70
95 rdf:rest N05dda3e4f741473a9f9b64ca71747723
96 N6c3d354a21d245ca9595b4f4cc187350 rdf:first sg:person.016647555142.20
97 rdf:rest Nd5f3c41de9204bb388bf6c19b28c9836
98 N76a56b00fc9d4a38ab25b360a5d38173 rdf:first sg:person.01013672342.45
99 rdf:rest N88c96ab3cf9b438c848d9a0235ac34d6
100 N850b5d553d924d09b98f88babbc25692 schema:familyName Holmes
101 schema:givenName William L.
102 rdf:type schema:Person
103 N88c96ab3cf9b438c848d9a0235ac34d6 rdf:first sg:person.0711142437.68
104 rdf:rest N67c9666f2e8e4770a84afdc21f925937
105 N897d8b19b3e84a0886b89d65379ff9f2 rdf:first N850b5d553d924d09b98f88babbc25692
106 rdf:rest rdf:nil
107 N8a442aba502542d2b6ff0e23615a9d16 schema:name dimensions_id
108 schema:value pub.1051880374
109 rdf:type schema:PropertyValue
110 Na8772a6295a649758655aa53ff45a11d schema:name Springer Nature
111 rdf:type schema:Organisation
112 Nac43307dd47b4b26a91e057b2cea5085 rdf:first N535f4655832b4c8aad9ddee1ddebcb20
113 rdf:rest N897d8b19b3e84a0886b89d65379ff9f2
114 Nbb7e5d59377943928db0d5cbdcaa30dc schema:name doi
115 schema:value 10.1007/978-3-642-71702-4_49
116 rdf:type schema:PropertyValue
117 Nc9bf2c75f9f84c6e9656834cbf694f42 rdf:first Ndf5520435e134e24bff4fcfa26bd5e11
118 rdf:rest Nac43307dd47b4b26a91e057b2cea5085
119 Nd34ddf0157a04bc7ad1c969cba5730b3 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 Nd5f3c41de9204bb388bf6c19b28c9836 rdf:first sg:person.0623417033.91
122 rdf:rest N429b8f47125f46f295f81abe385c9d4c
123 Ndf5520435e134e24bff4fcfa26bd5e11 schema:familyName Paoletti
124 schema:givenName Rodolfo
125 rdf:type schema:Person
126 Ne1c87b5d9ef64e7b9bdc86e7d50c38ac rdf:first sg:person.01017622015.68
127 rdf:rest N6c3d354a21d245ca9595b4f4cc187350
128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
129 schema:name Medical and Health Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
132 schema:name Medical Biochemistry and Metabolomics
133 rdf:type schema:DefinedTerm
134 sg:person.01013672342.45 schema:familyName Kamon
135 schema:givenName N.
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013672342.45
137 rdf:type schema:Person
138 sg:person.01017622015.68 schema:familyName Kajinami
139 schema:givenName K.
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017622015.68
141 rdf:type schema:Person
142 sg:person.01154062341.76 schema:familyName Mabuchi
143 schema:givenName H.
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154062341.76
145 rdf:type schema:Person
146 sg:person.01340001663.38 schema:affiliation grid-institutes:grid.9707.9
147 schema:familyName Takeda
148 schema:givenName R.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340001663.38
150 rdf:type schema:Person
151 sg:person.016647555142.20 schema:familyName Itoh
152 schema:givenName H.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016647555142.20
154 rdf:type schema:Person
155 sg:person.0623417033.91 schema:familyName Wakasugi
156 schema:givenName T.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623417033.91
158 rdf:type schema:Person
159 sg:person.0670213705.97 schema:familyName Takeda
160 schema:givenName M.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670213705.97
162 rdf:type schema:Person
163 sg:person.0711142437.68 schema:familyName Fujita
164 schema:givenName H.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711142437.68
166 rdf:type schema:Person
167 sg:person.0732262025.70 schema:familyName Michishita
168 schema:givenName I.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70
170 rdf:type schema:Person
171 grid-institutes:grid.9707.9 schema:alternateName The Second Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan
172 schema:name The Second Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan
173 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...